FindMyKOL

Thomas Olenginski, MD

Basic profile

Geisinger Health System

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionDanville, PA · NortheastSpecialtyRheumatologyFocusRheumatology/Immunology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Thomas Olenginski is a Rheumatology/Immunology physician affiliated with Geisinger Health System. OpenAlex indexes 37 publications with 996 citations (h-index 16).

Overview

Scholarship

indexed output and impact (OpenAlex)
37publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

996citations

Citations across these publications.

16h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
7companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Amgen Inc.
    Program year20252 payments
    $235
  • UCB, Inc.
    Program year20251 payment
    $142
  • Janssen Biotech, Inc.
    Program year20251 payment
    $79
All 10 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    28.5%
    Folate Analog Metabolic Inhibitor13.9%
    Methotrexate100%
    Part D≥48 patients
    TNF inhibitor10.5%
    Humira Pen32%Enbrel27%Enbrel Sureclick23%Humira18%
    Part D<11 patients

    + 3 more classes in this area

  • Hormonal (systemic)

    22.8%
    Parathyroid Hormone Analog15.7%
    Teriparatide70%Forteo30%
    Part D≥21 patients
    Parathyroid Hormone-Related Peptide Analog7.1%
    Tymlos100%
    Part D≥13 patients
  • Musculoskeletal

    13.8%
    Xanthine oxidase inhibitor7.5%
    Allopurinol100%
    Part D≥29 patients
    Nonsteroidal Anti-inflammatory Drug2.6%
    Diclofenac Sodium66%Nabumetone34%
    Part D<11 patients

    + 3 more classes in this area

Where care is delivered (Part B)87.7% facility · 12.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”